找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Biologics in General Medicine; Wolf-Henning Boehncke,Heinfried H. Radeke Book 2007 Springer-Verlag Berlin Heidelberg 2007 Arthritis.Monito

[復(fù)制鏈接]
樓主: CROSS
11#
發(fā)表于 2025-3-23 11:33:32 | 只看該作者
12#
發(fā)表于 2025-3-23 14:30:32 | 只看該作者
Biologics in Crohn’s Disease and Ulcerative Colitis: Focus on Tumor Necrosis Factor Antagonistsnagement options for these diseases. The discovery of immunologic and inflammatory mediators, in particular, has paved the way for clinical research with biologic agents in this area. Although conventional treatments remain viable options for some patients, those who are intolerant to these agents a
13#
發(fā)表于 2025-3-23 18:06:12 | 只看該作者
Multiple Sclerosis: New Immunobiologicsworldwide by this disease, and the relapsing-remitting form of MS exhibits a gender disequilibrium of 3:1 for female affliction. There are several lines of evidence that multiple sclerosis is an autoimmune disease, which may be modified by genetic factors (see review in .). Following the initial for
14#
發(fā)表于 2025-3-24 01:17:16 | 只看該作者
Biologics in Cutaneous Lymphomatracutaneous disease at the time of diagnosis. They can be distinguished into cutaneous T-cell lymphomas (CTCL), cutaneous B-cell lymphomas (CBCL) and the rare precursor dendritic cell neoplasms. The PCL are now classified in the new WHO-EORTC classification (.; Table 14.1).
15#
發(fā)表于 2025-3-24 04:16:15 | 只看該作者
16#
發(fā)表于 2025-3-24 08:47:31 | 只看該作者
17#
發(fā)表于 2025-3-24 10:43:38 | 只看該作者
Summary and Critical Reflection of efficacy and/or safety problems like infusion reactions. Therefore, chimaeric antibodies such as infliximab (Remicade) were developed, reducing immunogenicity by replacement of the murine Fc part by the human counterpart.
18#
發(fā)表于 2025-3-24 15:39:32 | 只看該作者
19#
發(fā)表于 2025-3-24 20:37:49 | 只看該作者
20#
發(fā)表于 2025-3-25 01:20:15 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-5 19:33
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
拉孜县| 乌拉特后旗| 垫江县| 大安市| 临沧市| 淮滨县| 古丈县| 明溪县| 莆田市| 泾川县| 铜陵市| 开江县| 贵州省| 玛沁县| 南开区| 榆社县| 长治县| 根河市| 辽宁省| 平山县| 灵石县| 西藏| 论坛| 吴堡县| 汉源县| 武宁县| 珲春市| 凤台县| 合水县| 天水市| 稻城县| 信阳市| 张家口市| 吉林市| 中宁县| 龙游县| 赤城县| 江永县| 佛学| 南通市| 山丹县|